In addition, FBXO22 can also deploy nondegradative ubiquitination to drive metastasis by mediating K63‐linked polyubiquitination of the kinase LKB1, a modification that inhibits the tumor‐suppressive LKB1–AMPK signaling axis [181]. Here, STK11 is linked to neoplasm.